We present a phenotype-genotype correlation analysis in 12 patients with cystic fibrosis (CF) carrying the mutation R334W in the CFTR gene. The clinical data obtained for this group were compared with the clinical data of AF508/ AF508 patients. Current age and age at diagnosis were significantly higher in the R334W mutation group (p=0.028 and p=0.0001). We found a lower rate of Pseudomonas aeruginosa colonisation in patients carrying the R334W mutation, although the difference was not found to be statistically significant. However, we found a statistically significant higher age of onset of Pseudomonas aeruginosa colonisation (p=0.0036) in the group of patients with the R334W mutation. Thirty three percent of R334W patients were pancreatic insufficient, significantly lower than the AF508/AF508 patients (p=0.004). We also found that the weight expressed as a percentage of ideal weight for height was significantly higher in patients with the R334W mutation (p=0.0028).
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Our results provide new data to support that patients with the R334W mutation suffer less severe expression of the disease and that the disease can be diagnosed later, as reported by Estivill et al. ' 4 The proportion of pancreatic insufficient patients with the R334W mutation in our study is lower (33%) when compared to the proportion of pancreatic insufficient patients in the paper by Estivill et al'4 (60%). In our study the number of pancreatic sufficient patients with R334W varied according to the age at which pancreatic status was assessed, the later the age the smaller the number of pancreatic sufficient patients, with most patients being pancreatic sufficient at 20 years of age. It may suggest that pancreatic function in this group of patients declines with age. This fact is supported by the pancreatic status found in patients 10, 11, and 12, belonging to the same family. While patients 10 and 12 are at the lower limit of pancreatic sufficiency, patient 11 has minimal pancreatic insufficiency.
Chronic infection with PA is the main cause of morbidity and mortality in CF patients. We did not find statistically significant differences with regard to lung colonisation by this pathogenic bacteria, although a lower rate of colonisation was found in R334W patients. A slightly higher proportion of lung colonisation in R334W patients compared to AF508/AF508 patients has previously been reported,14 although the lung colonisation was referred to as bacterial pathogens in that report. On the other hand, a significant higher age at colonisation was found in our group of patients suggesting that R334W may be a lower risk allele than AF508 for the acquisition of PA.
Interfamilial and intrafamilial clinical diversity for pancreatic insufficiency and the variation in pulmonary disease indicates that other factors, either genetic or environmental, must affect the severity and progression of the disease. In fact, it has been recently shown that the severity of CF in mice can be modified by at least one unlinked genetic locus."5 Environmental factors, such as age at diagnosis, a previous affected sib, medical care, or degree of compliance with treatment regimens, may further contribute to the variatiation of the clinical spectrum of the disease in CF patients.
